Benefit — FDA Diversity Plan stance
What Snapshot-grade Diversity Plan monitoring actually saves you
The rule is measurable representative-population monitoring. The consequence of NOT having dated independent evidence when FDA raises the Diversity Plan question at Type C or pre-NDA is a very different exposure profile.
The three moments where it matters
- Type C meeting. Reviewer asks about AI-driven eligibility monitoring against Diversity-Plan targets. Dated independent evidence lets Reg Affairs answer with a record instead of a promise.
- Pre-NDA / pre-BLA milestone. Diversity Plan appendix commitments come due. AI-eligibility monitoring evidence is the audit trail behind those commitments.
- Complete Response Letter risk. Diversity-Plan-deficit CRLs have driven public pivotal-trial re-runs costing $10M-$100M+ per program. Preventive monitoring shifts the risk profile.
Dollar frame
CRL re-run cost: $10M-$100M+ per program for a Diversity-Plan-deficit-driven pivotal-trial re-run — public precedent across multiple oncology + neurology + cardiovascular programs 2023-2026.
Post-marketing commitment (PMC): $5M-$50M+ per additional PMC trial when the representation gap is not closed before approval.
Preventive stance cost: $499 Snapshot documents monitoring. Under Type C / pre-NDA review, that dated evidence frequently keeps the Diversity Plan appendix stance defensible.
Who at your org cares
- VP Regulatory Affairs — Type C + pre-NDA meeting stance
- Chief Medical Officer — medical-affairs credibility on equity
- Head of Clinical Development — Diversity Plan appendix accuracy
- Chief Compliance Officer — sponsor SOP + carrier questionnaire response
- Investor Relations + Diligence Partners — equity-of-access narrative
What "having it" looks like
Green: Snapshot on file. Independent-verifier signature. Patient-group-level monitoring documented before the Type C meeting. Reviewer conversation opens with the sponsor on the credibility front-foot.
Red: No independent evidence. The clinical-AI vendor's dashboard is the only "monitoring" on file. FDA reviewer's first follow-up question surfaces the gap. The Snapshot's 3 fix-first items become the immediate remediation plan.
$499. 3 business days.
The dated record FDA + your Reg Affairs + your Chief Medical Officer want on file BEFORE the Type C or pre-NDA question lands.
Buy $499